10x Genomics (NASDAQ:TXG) Issues Quarterly Earnings Results, Beats Expectations By $0.05 EPS

10x Genomics (NASDAQ:TXG) released its earnings results on Thursday. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.05, Zacks reports. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. 10x Genomics updated its Q4 2025 guidance to EPS.

10x Genomics Price Performance

Shares of NASDAQ:TXG traded down $0.49 during trading on Thursday, hitting $13.00. 3,407,211 shares of the company were exchanged, compared to its average volume of 3,203,421. The firm’s 50 day moving average price is $12.81 and its 200-day moving average price is $11.68. 10x Genomics has a 12-month low of $6.78 and a 12-month high of $17.25. The stock has a market capitalization of $1.62 billion, a P/E ratio of -18.57 and a beta of 2.13.

Insider Buying and Selling

In related news, CEO Serge Saxonov sold 9,348 shares of the business’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $128,908.92. Following the completion of the sale, the chief executive officer directly owned 945,892 shares of the company’s stock, valued at $13,043,850.68. The trade was a 0.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Benjamin J. Hindson sold 7,486 shares of the firm’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $103,231.94. Following the transaction, the insider directly owned 440,888 shares in the company, valued at approximately $6,079,845.52. The trade was a 1.67% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 39,149 shares of company stock worth $539,865 in the last ninety days. 9.39% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On 10x Genomics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Orion Porfolio Solutions LLC purchased a new position in shares of 10x Genomics during the second quarter worth approximately $158,000. CANADA LIFE ASSURANCE Co boosted its stake in 10x Genomics by 167.9% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 22,069 shares of the company’s stock worth $256,000 after purchasing an additional 13,831 shares during the period. Exome Asset Management LLC acquired a new stake in 10x Genomics during the 2nd quarter worth $1,895,000. Corient Private Wealth LLC purchased a new position in 10x Genomics during the 2nd quarter worth $597,000. Finally, Captrust Financial Advisors acquired a new position in 10x Genomics in the second quarter valued at $420,000. Hedge funds and other institutional investors own 84.68% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on TXG shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of 10x Genomics in a report on Tuesday, October 14th. Zacks Research upgraded 10x Genomics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 9th. Morgan Stanley cut their target price on shares of 10x Genomics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 12th. UBS Group raised their target price on shares of 10x Genomics from $12.00 to $13.00 and gave the company a “neutral” rating in a report on Friday, August 8th. Finally, Wall Street Zen upgraded shares of 10x Genomics from a “hold” rating to a “buy” rating in a report on Friday, October 3rd. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $13.65.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.